No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Diagnostics & Research
Headquartered in Hägersten, Sweden, and established in 2004, Devyser Diagnostics AB (publ) specializes in the development, manufacturing, and global sale of advanced diagnostic kits and solutions for DNA testing. The company's innovative products are crucial for genetic analysis in key medical areas, including hereditary diseases, oncology, and post-transplantation monitoring. Devyser offers a broad array of diagnostic tools, covering applications such as post-transplant management, thalassemia screening, and the detection of various cancers like breast, colorectal, and ovarian. Their portfolio also extends to non-invasive fetal RHD screening, diagnostics for inherited conditions, cystic fibrosis, cardiovascular issues, male infertility, and rapid aneuploidy analysis, complemented by essential accessories. These solutions are utilized for diverse purposes, from diagnosing genetic disorders and guiding targeted cancer treatments to ensuring thorough follow-up care for transplant patients. Furthermore, Devyser provides specialized software programs, including Amplicon Suite and Advyser, which facilitate the processing, analysis, and interpretation of test results, enabling efficient marker screening and patient sample tracking. The company's operations span Sweden, the broader European market, the Middle East, Africa, North and South America, and Asia.
devyser.comNo one on the platform currently holds DVYSR.ST.
No tracked institution reports a position in DVYSR.ST as of their last filing.
No one on the platform has traded DVYSR.ST yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | — | — | — | |||
| Rev. Growth % | 15.5% | 30.7% | ||||
| Profit Margin % | -3.4% | -24.4% | ||||
| Free Cash Flow Margin % | 2.7% | -38.8% | ||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $246M | -3.5% | $0.72 | $0.55–$0.89 | — | 2 |
| 2027 | $298M | +20.9% | $1.91 | $1.69–$2.12 | — | 2 |
| 2028 | $359M | +20.5% | $3.42 | $3.40–$3.44 | — | 2 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 4 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-20 | $0.27 | $0.10 | -63.0% |
| 2026-04-27 | $0.15 | $0.17 | +14.2% |
| 2026-02-12 | $0.42 | $0.80 | +90.5% |
| 2025-11-05 | $0.29 | $-0.17 | -157.5% |
| 2025-07-22 | $-0.13 | $0.20 | +250.0% |
| 2025-04-29 | $-0.54 | $-1.24 | -129.6% |
| 2025-02-13 | $-0.57 | $-0.19 | +66.7% |
| 2024-10-30 | $-1.07 | $-1.41 | -31.8% |
| -1.13% |
| $3.7B |
| — |
| HUM.STHumana AB (publ) | $67.80 | +0.00% | $3.2B | — |
| OSSD.STOssDsign AB (publ) | $3.57 | +0.85% | $395M | — |
Source: Financial Modeling Prep · peers by sector/industry